mercaptopurine and Lung-Neoplasms

This chapter introduces some fundamental results in survival analysis. We first describe what is censored failure time data and how to interpret the failure time distribution. Two nonparametric methods for estimating the survival curve, the life table estimator and the Kaplan-Meier estimator, are demonstrated. We then discuss the two-sample problem and the usage of the log-rank test for comparing survival distributions between groups. Lastly, we discuss in some detail the proportional hazards model, which is a semiparametric regression model specifically developed for censored data. All methods are illustrated with artificial or real data sets.

Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Humans; Leukemia; Life Tables; Lung Neoplasms; Mercaptopurine; Proportional Hazards Models; Recurrence; Survival Analysis

Diffuse pulmonary diseases seen in patients receiving chemotherapy have a wide variety of etiologies including infection, involvement with the underlying disease, injury from radiation or diagnostic agents, and toxicity from chemotherapeutic drugs. In addition to concomitantly used therapeutic agents, previously administered cytotoxic drugs may enhance the toxicity of radiotherapy and vice versa. Together with the clinician, the radiologist may be able to assess the probability of drug-induced lung disease by correlating radiographic and clinical data. Useful clinical data include signs and symptoms related to the lungs, pulmonary function test results, dose and schedule of drug administration, and information concerning concomitant or previous drug or radiation therapy. Useful radiographic data include the distribution of densities seen on the chest radiograph, the presence or absence of thoracic adenopathy, and the presence or absence of pleural effusion. The diagnosis is difficult, and thus the incidence of clinical and subclinical drug-induced pneumonitis is not accurately known.

Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Busulfan; Carmustine; Cyclophosphamide; Female; Humans; Lomustine; Lung Diseases; Lung Neoplasms; Male; Mercaptopurine; Methotrexate; Middle Aged; Pulmonary Fibrosis; Radiography

Topics: Adenocarcinoma; Anemia; Bone Marrow Diseases; Carcinoma, Squamous Cell; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Colonic Neoplasms; Humans; Leukopenia; Lung Neoplasms; Mercaptopurine; Nausea; Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Thrombocytopenia; Vomiting

Topics: Breast Neoplasms; Clinical Trials as Topic; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Lymphoma; Melanoma; Mercaptopurine; Neoplasms

Childhood adrenocortical carcinoma (ACC) is a rare tumor and its association with acute lymphoblastic leukemia (ALL) is even rarer. One such case is discussed in this case report. A 3-year-old patient was concomitantly diagnosed with ALL and an initially nonmetastatic ACC. Management started by following the Total XV protocol without a window phase. Left adrenalectomy was conducted after the consolidation phase. Recurrence of a mass at the tumor bed was discovered at week 33 of the continuation phase. Reexcision was conducted, followed by the administration of an ACC protocol including cisplatin, etoposide, and doxirubicin. Mitotane was added when a pulmonary metastasis was discovered and then stopped after the patient suffered from an arachnoid cyst and speech difficulties. The ALL protocol was resumed from week 34 of the continuation phase. Progression of pulmonary nodules was noted after week 45. A pulmonary metastectomy was performed. The ALL protocol was resumed up to week 51 with a good response as proven by assessment of minimal residual disease. A further recurrence was diagnosed at the abdominal tumor bed with a paravertebral mass and a pulmonary nodule. The patient was assigned to palliative treatment and died after a 32-month survival. Such rare associations need more extensive discussions of the best possible management in scientific literature.

Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Doxorubicin; Etoposide; Fatal Outcome; Humans; Language Development Disorders; Lung Neoplasms; Mercaptopurine; Methotrexate; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Nephrectomy; Pneumonectomy; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Colonic Neoplasms; Colonic Polyps; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Idarubicin; Indoles; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Mercaptopurine; Methotrexate; Middle Aged; Neoplasms, Second Primary; Pyrroles; Remission Induction; Sunitinib; Time Factors; Tretinoin

Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Child; Herpesvirus 4, Human; Humans; Immunosuppressive Agents; Lung Neoplasms; Lymphoma, B-Cell; Male; Mercaptopurine; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome

The isolation and characterization is described of four novel cyclic polyethers, bistramides B [2], C [3], D [4], and K [5], which are closely related to the previously reported bistramide A [1] from the New Caledonian urochordata Lissoclinum bistratum. The structures of these metabolites were defined by spectroscopic methods. The four compounds exhibited in vitro cytotoxicity toward six tumor cell lines, including the human non-small cell lung carcinoma (NSCLC-N6) line. Cytofluorimetric analysis with bistramide K showed a complete block of NSCLC-N6 cells in the G1 phase. Bistramide D and particularly bistramide K are less toxic than bistramides A, B, and C and are thereby effective in vivo against NSCLC-N6.

Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Survival; Ethers, Cyclic; Humans; Lung Neoplasms; Magnetic Resonance Spectroscopy; Molecular Structure; Tumor Cells, Cultured; Urochordata

Topics: Adult; Aged; Carcinoma, Small Cell; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Mercaptopurine; Middle Aged

Antitumor activities of a combination chemotherapy with a water-soluble nitrosourea, 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride (ACNU), and a single dose of 6-thioguanine were studied using three obstinate murine tumor systems, i.e., Lewis lung carcinoma, B16 melanoma, and an advanced stage of L1210 leukemia systems. Therapeutically synergistic effect was observed either definitely against 1- or 2-day-old Lewis lung carcinoma and 6-day-old L1210 leukemia or moderately against 1-day-old B16 melanoma. Single intravenous treatment on day 7 after subcutaneous implantation of Lewis lung carcinoma, when the tumors had already metastasized to the lungs, produced a significant regression of tumor and a significant increment in survival time of tumor-bearing mice. In comparative studies, the combination of ACNU and 6-thioguanine showed a greater and a wider spectrum of antitumor activities against these tumors than those obtained by the combination with ACNU and a single dose of 5-fluorouracil, methotrexate, or 6-mercaptopurine. Increment in lethal toxicity for normal and tumor-bearing mice was not observed by the combination of ACNU and 6-thioguanine in contrast to definite increases in this toxicity by the combination of ACNU and 5-fluorouracil. The present experimental results may suggest the clinical utility of the combination chemotherapy with ACNU and 6-thioguanine in the treatment of several solid tumors as well as acute leukemias.

Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Drug Synergism; Drug Therapy, Combination; Female; Injections, Intraperitoneal; Injections, Intravenous; Leukemia L1210; Lung Neoplasms; Male; Melanoma; Mercaptopurine; Mice; Neoplasms, Experimental; Nimustine; Nitrosourea Compounds; Thioguanine

Cells obtained from the Nettesheim lung carcinoma of DBA/2 mice, a heterogenous population grown s.c., were cultured as monolayers. These cells were serially subcultured and cloned twice, and a clone was selected for further study. This clone produced malignant tumors at the injected site when injected s.c. into male DBA/2 or C57BL/L x DBA/2 F1 mice. Referred as KLN205, this cell line had the highest rate of lung colony formation on i.v. injection. It was subcultured for over 15 generations, and its cytological characteristics were investigated. The s.c. and lung colony growth were examined histologically. The effects of treatment with two antimetabolite drugs, arabinosyl-6-mercaptopurine (NSC 406021) and 6-selenoguanosine (NSC 137679) were determined in culture and in vivo. The former was relatively ineffective; the latter was very effective both in vivo and in vitro. Several drugs used clinically for the treatment of lung cancer were also tested. This established and characterized cell line is proposed as a potential model for testing other chemotherapeutic treatments.

Topics: Animals; Carcinoma, Squamous Cell; Cell Division; Clone Cells; Guanosine; Lung Neoplasms; Male; Mercaptopurine; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Transplantation; Neoplasms, Experimental; Organoselenium Compounds; Selenium; Transplantation, Homologous; Transplantation, Isogeneic

Cytotoxic drugs, principally bleomycin, methotrexate and busulfan, have been associated with pulmonary toxicity. Cytotoxic drug-induced lung disease may be difficult to establish with certainty because other causes of pulmonary disease are frequently present. We discuss the clinical, roentgenographic and histologic effects of the administration of bleomycin, methotrexate, busulfan and other cytotoxic agents on the lungs and suggest that these agents may also cause pulmonary malignancies. We note the importance of careful patient monitoring and withdrawal of a demonstrated offending agent.

Topics: Antibiotics, Antineoplastic; Azathioprine; Bleomycin; Busulfan; Cyclophosphamide; Dose-Response Relationship, Drug; Humans; Lung Diseases; Lung Neoplasms; Mercaptopurine; Methotrexate; Radiography

The differential distribution of a series of antineoplastic agents in metastatic tissues compared to their respective primary tumors has been investigated in one rat and two mouse experimental tumor systems, ie, the intramuscular Lewis lung carcinoma (3LL) of C57BL/6 mice, which gives rise to spontaneous lung metastases, the intratibial Sarcoma 180 (S180) of CD1 mice, which induces macroscopic metastases to the lymph nodes, and the Walker 256 carcinosarcoma of CD rats, which also metastasizes to the lymph nodes. The results described in this paper show that the concentrations of adriamycin, daunorubicin, cyclophosphamide and its alkylating metabolites, hydroxyurea, 1-methyl-1-nitrosourea, and 6-mercaptopurine are much higher in the pulmonary metastases of 3LL and/or in the lymph node metastases of S180 than the concentrations measured in the primary tumor. In the Walker 256 tumor system the distribution of adriamycin appears to follow the same pattern observed for the mouse tumors. Only for methotrexate (in the 3LL tumor) is the difference in the concentrations at the two sites not so evident. These findings are discussed in relation to the comparatively greater sensitivity of metastases to chemotherapy.

Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Carcinoma 256, Walker; Cyclophosphamide; Daunorubicin; Doxorubicin; Female; Hydroxyurea; Lung Neoplasms; Lymphatic Metastasis; Male; Mercaptopurine; Methotrexate; Methylnitrosourea; Mice; Neoplasm Metastasis; Neoplasms, Experimental; Rats; Sarcoma, Experimental

Topics: Acute Disease; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Female; Humans; Kidney Neoplasms; Leukemia, Lymphoid; Lung Neoplasms; Mercaptopurine; Methotrexate; Neoplasm Metastasis; Prednisone; Vincristine; Wilms Tumor

The effect of hydrocortisone on blood-borne tumor metastasis was studied in an i.v. inoculation experiment with Ehrlich hypotetraploid clone 1, Ehrlich hypotetraploid stock, and Ehrlich hyperdiploid stock tumors. The administration of hydrocortisone before tumor inoculation resulted in increased tumor take, reduced mean survival time of mice, and concentration of tumor metastasis in a specific organ (i.e., lung metastasis for Ehrlich hypotetraploid clone 1 tumor, and liver metastasis for Ehrlich hypotetraploid stock and Ehrlich hyperdiploid stock tumors). Enhancement of tumor metastasis, as induced by hydrocortisone pretreatment, was not reproduced by the administration of 6-mercaptopurine, testosterone, or estradiol. The progress of tumor death in hydrocortisone-conditioned mice was not affected by either heparin or dextran sulfate. This indicated that the effect of hydrocortisone on tumor metastasis was independent of the effect of these agents on immune reaction or blood coagulation. In the tracer experiment with 125-I-labeled tumor cells, hydrocortisone pretreatment significantly increased over the control the intrapulmonary retention of Ehrlich hypotetraploid clone 1 tumor cells from 1 through 72 hr after tumor inoculation, the time lag required for the establishment of metastatic foci in the lung. The arrest of Ehrlich hypotetraploid stock and Ehrlich hyperdiploid stock tumors in the liver was also temporarily increased by hydrocortisone pretreatment. No correlation was found between tumor cell size and differential distribution of metastatic tumors with 3 Ehrlich tumors. An attempt was made to use this blood-borne metastasis system for chemotherapeutic study. Administration of cyclophosphamide gave rise to a significant prolongation of survival time and often to complete prevention of tumor metastasis in hydrocortisone-conditioned mice.

Topics: Animals; Carcinoma, Ehrlich Tumor; Cell Line; Cyclophosphamide; Dextrans; Estradiol; Female; Heparin; Hydrocortisone; Injections, Intravenous; Liver Neoplasms; Lung Neoplasms; Mercaptopurine; Mice; Mice, Inbred ICR; Neoplasm Metastasis; Neoplastic Cells, Circulating; Stimulation, Chemical; Testosterone; Time Factors

Drug screening trials and general treatment of solid tumours in advanced cancer patients have been concerned only with the site of primary origin, regardless of where metastases might have seeded. Since the environment for tumour growth can differ appreciably at various anatomical sites, an investigation was undertaken to determine the effect of metastatic site on response to chemotherapy. Data from 1961 to 1965 of the screening trials of the Eastern Clinical Drug Evaluation Program were utilized. Response and location data extensive enough for analysis represented 6 sites of primary origin and 6 metastatic site groups, totalling 1687 lesions. Analysis of percentage reduction in tumour size after chemotherapy regimens of up to 60 days revealed a significant amount of variation associated with metastatic sites and a non-significant amount associated with sites of primary origin. Advanced primary tumours showed marked variation in responsiveness and some showed a difference in response to different drug groups. Generally, metastases responded better than the advanced primaries from which they were derived, except for those from breast tumours.

Topics: Antineoplastic Agents; Breast Neoplasms; Chlorambucil; Female; Fluorouracil; Genital Neoplasms, Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Melanoma; Mercaptopurine; Mitomycins; Neoplasm Metastasis; Neoplasms

Topics: Adult; Antineoplastic Agents; Choriocarcinoma; Colchicine; Dactinomycin; Daunorubicin; Female; Flavonoids; Humans; Lung Neoplasms; Melphalan; Mercaptopurine; Methotrexate; Middle Aged; Mitomycins; Neoplasm Metastasis; Olivomycins; Pneumonectomy; Pregnancy; Uterine Neoplasms; Vinblastine

Topics: Adolescent; Asparaginase; Child; Chlorambucil; Cobalt Radioisotopes; Cyclophosphamide; Female; Humans; Lung Neoplasms; Male; Mandible; Mandibular Neoplasms; Mercaptopurine; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pregnenolone; Radiography; Sarcoma, Ewing; Vinblastine

Topics: Adolescent; Adult; Antineoplastic Agents; Choriocarcinoma; Cyclophosphamide; Dactinomycin; Female; Follow-Up Studies; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Infant; Lung Neoplasms; Male; Mechlorethamine; Mercaptopurine; Methotrexate; Middle Aged; Neoplasm Metastasis; Pregnancy; Prostatic Neoplasms; Sarcoma; Teratoma; Testicular Neoplasms; Thoracic Neoplasms; Thyroid Neoplasms; Triaziquone; Uterine Neoplasms; Vinblastine

Topics: Animals; Azaguanine; Carcinoma, Ehrlich Tumor; Clone Cells; Drug Resistance; Guanosine; Injections, Intravenous; Lung; Lung Neoplasms; Mercaptopurine; Methods; Mice; Mice, Inbred ICR; Microspheres; Mutagens; Neoplasm Transplantation; Transplantation, Homologous

Topics: Animals; Benzyl Compounds; Brain; DDT; Electron Spin Resonance Spectroscopy; Free Radicals; Humans; Kinetics; Leukemia; Liver; Lung Neoplasms; Lymphocytes; Mathematics; Melphalan; Mercaptopurine; Mice; Neoplasm Metastasis; Neoplasms; Neoplasms, Experimental; Nitrosourea Compounds; Rats; Thiotepa; Time Factors

Topics: Adult; Choriocarcinoma; Female; Humans; Hysterectomy; Lung Neoplasms; Mercaptopurine; Methotrexate; Neoplasm Metastasis; Postoperative Complications; Pregnancy

Topics: Adenine Nucleotides; Adult; Animals; Antibiotics, Antineoplastic; Arabinose; Carcinoma, Squamous Cell; Cricetinae; Dogs; Humans; Hypoxanthines; Kidney; Leukemia, Lymphoid; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Mice; Middle Aged; Neoplasms; Nucleosides; Nucleotidases; Nucleotides; Phosphorus; Rabbits; Sulfur Isotopes; Time Factors; Tritium

Topics: Adult; Aged; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma, Bronchogenic; Drug Synergism; Humans; Hydroxypropiophenone; Lung Neoplasms; Mercaptopurine; Middle Aged; Neoplasm Metastasis; Neurotransmitter Agents; Reserpine; Time Factors; Urethane

Topics: Adolescent; Adult; Antineoplastic Agents; Choriocarcinoma; Dactinomycin; Female; Humans; Lung Neoplasms; Mercaptopurine; Methotrexate; Neoplasm Metastasis; Pregnancy

Topics: Adenocarcinoma; Aged; Bone Marrow Diseases; Erythrocytes; Humans; Leukemia; Lung Neoplasms; Male; Megakaryocytes; Mercaptopurine; Middle Aged; Thiotepa; Thrombocythemia, Essential

Topics: Abortion, Septic; Adult; Choriocarcinoma; Diagnosis, Differential; Diagnostic Techniques, Surgical; Female; Humans; Hysterectomy; Lung Neoplasms; Mercaptopurine; Methotrexate; Neoplasm Metastasis; Pelvic Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy Tests; Pregnancy, Ectopic

Topics: Adult; Choriocarcinoma; Chorionic Gonadotropin; Female; Humans; Immunoassay; Lung Neoplasms; Mercaptopurine; Methotrexate; Neoplasm Metastasis; Pregnancy; Vaginal Neoplasms

Topics: Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Cytarabine; Female; Fluorouracil; Humans; Lung Neoplasms; Mercaptopurine; Methotrexate; Neoplasms; Prognosis; Time Factors

Topics: Angiography; Calcinosis; Choriocarcinoma; Female; Lung Neoplasms; Mercaptopurine; Methotrexate; Neoplasm Metastasis; Pregnancy

Topics: Androgens; Antibiotics, Antineoplastic; Antineoplastic Agents; Ascorbic Acid; Azirines; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Synergism; Fluorouracil; Glucocorticoids; Humans; Hydrazines; Injections, Intramuscular; Injections, Intravenous; Lectins; Lung Neoplasms; Mechlorethamine; Mercaptopurine; Mesothelioma; Methotrexate; Phenylbutazone; Pleural Neoplasms; Thiotepa; Vinblastine

Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Dactinomycin; Drug Synergism; Humans; Lung Neoplasms; Mercaptopurine; Methotrexate; Mitomycins; Neoplasm Metastasis; Radiotherapy Dosage; Triaziquone

Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Azirines; Bronchial Neoplasms; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Synergism; Humans; Hydrazines; Injections, Intramuscular; Injections, Intravenous; Lung Neoplasms; Mechlorethamine; Mercaptopurine; Methotrexate; Middle Aged; Vinblastine

Topics: Anemia, Aplastic; Antibiotics, Antineoplastic; Antineoplastic Agents; Azirines; Bronchial Neoplasms; Drug Synergism; Fluorouracil; Humans; Hydrazines; Injections, Intramuscular; Injections, Intravenous; Lectins; Lung Neoplasms; Mechlorethamine; Mercaptopurine; Methotrexate; Pleural Neoplasms; Vinblastine

Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Azirines; Bronchial Neoplasms; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Synergism; Fluorouracil; Humans; Hydrazines; Injections, Intravenous; Lung Neoplasms; Mechlorethamine; Mercaptopurine; Methotrexate; Neoplasm Metastasis; Pleural Neoplasms; Vinblastine

Topics: Antineoplastic Agents; Azirines; Bronchial Neoplasms; Cyclophosphamide; Drug Synergism; Fluorouracil; Humans; Hydrazines; Injections, Intramuscular; Injections, Intravenous; Lung Neoplasms; Mercaptopurine; Methotrexate; Vinblastine

Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Drug Synergism; Female; Fluorouracil; Humans; Hydrazines; Injections, Intramuscular; Injections, Intravenous; Lung Neoplasms; Male; Mechlorethamine; Mercaptopurine; Methotrexate; Middle Aged; Vinblastine

Topics: Antineoplastic Agents; Azirines; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Synergism; Fluorouracil; Humans; Hydrazines; Lung Neoplasms; Mercaptopurine; Mesothelioma; Methotrexate; Neoplasm Metastasis; Vinblastine

Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Drug Synergism; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Hydrazines; Injections, Intramuscular; Injections, Intravenous; Lectins; Lung Neoplasms; Mechlorethamine; Mercaptopurine; Methotrexate; Mouth Neoplasms; Neoplasm Metastasis; Pharyngeal Neoplasms; Urogenital Neoplasms; Vinblastine

Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Azirines; Betamethasone; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Lectins; Lung Neoplasms; Male; Mechlorethamine; Mercaptopurine; Methotrexate; Middle Aged; Pleural Neoplasms; Sarcoma; Vinblastine

Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Squamous Cell; Culture Techniques; Flavonoids; Fluorouracil; HeLa Cells; Humans; Lung Neoplasms; Melphalan; Mercaptopurine; Methods; Mitomycins; Neoplasms; Rectal Neoplasms; Stomach Neoplasms

Topics: Choriocarcinoma; Female; Humans; Hydatidiform Mole, Invasive; Lung Neoplasms; Mercaptopurine; Neoplasm Metastasis; Neoplasms; Pregnancy; Prognosis; Surgical Procedures, Operative; Uterine Neoplasms

Topics: Adenocarcinoma; Blood Cell Count; Carcinoma, Renal Cell; Epoetin Alfa; Erythropoietin; Geriatrics; Humans; Kidney Neoplasms; Lung Neoplasms; Mercaptopurine; Neoplasm Metastasis; Neoplasms; Neoplasms, Second Primary; Nephrectomy

Topics: Antineoplastic Agents; Brain Neoplasms; Castration; Choriocarcinoma; Female; Humans; Hydatidiform Mole, Invasive; Hysterectomy; Lung Neoplasms; Mercaptopurine; Methotrexate; Neoplasm Metastasis; Neoplasms; Pregnancy; Trophoblastic Neoplasms; Uterine Neoplasms

Topics: Choriocarcinoma; Electrocardiography; Female; Humans; Hydatidiform Mole; Lung Neoplasms; Mercaptopurine; Methotrexate; Neoplasm Metastasis; Pregnancy; Uterine Neoplasms

Topics: Aminopterin; Antimetabolites; Biomedical Research; Carcinoma, Bronchogenic; Humans; Lung Neoplasms; Mercaptopurine; Triethylenemelamine; X-Rays